In Focus channel feed

The aca­d­e­m­ic-en­tre­pre­neur mod­el built com­pa­nies and mint­ed mil­lion­aires. What hap­pens when one of its ear­li­est ad­vo­cates quits?  

Last year
People
Startups

Lutetium, ac­tini­um or lead: Can iso­tope type of­fer an edge in ra­dio­ther­a­py?

Last year
Manufacturing

'If you could have the next Prozac, that’s in­tox­i­cat­ing': Sage’s post­par­tum de­pres­sion tri­umph and the fail­ure that fol­lowed

Last year
R&D
Pharma

Roger Perl­mut­ter lights up the bi­o­log­i­cal dark, build­ing a new phar­ma force in Eikon and its su­per­pow­ered mi­cro­scopes

Last year
Startups
R&D

Grail has big plans for its blood can­cer tests. The first step: Find­ing a new own­er

Last year
Diagnostics

Why 2023 was the year of un­so­licit­ed ac­qui­si­tion bids — and why next year like­ly won’t be

Last year
Deals

Lil­ly, No­vo’s bet on heart dis­ease starts to take shape, and 2024 could be a piv­otal year for their GLP-1s 

Last year
R&D

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Last year
R&D
Cell/Gene Tx

Aviv Regev leads Genen­tech's next rev­o­lu­tion with AI

Last year
R&D
AI

Up­dat­ed: Will the UK’s triple-pronged ap­proach ease pric­ing, reg­u­la­to­ry and fi­nan­cial bot­tle­necks?

Last year
Pharma

Ful­ly syn­thet­ic genome nears com­ple­tion in a step to­ward un­rav­el­ing ge­net­ic mys­ter­ies

Last year
R&D
Discovery

mR­NA’s next trick? Re­pro­gram­ming off-the-shelf cell ther­a­pies for can­cer and au­toim­mune dis­eases

Last year
Cell/Gene Tx

Ra­dio­phar­ma CD­MOs nav­i­gate sup­ply chain, raw ma­te­r­i­al chal­lenges as de­mand goes nu­clear

Last year
Manufacturing

Af­ter the ap­plause: New ef­fi­ca­cy ex­pec­ta­tions in urothe­lial can­cer af­ter Pad­cev-Keytru­da da­ta re­veal

Last year
R&D
Pharma

You get an ADC, you get an ADC: Phar­mas bite on on­col­o­gy’s buzzi­est class

Last year
Deals
R&D

Af­ter years of hype, the first AI-de­signed drugs fall short in the clin­ic

Last year
AI

Most de­tailed hu­man brain map yet is ‘lay­ing the foun­da­tion for find­ing fu­ture cures’

Last year
R&D

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

Last year
R&D

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

Last year
Discovery

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

Last year
Financing
Startups

Dana-Far­ber, Brigham breakup could lead to a rip­ple ef­fect for CGT clin­i­cal tri­als for can­cer

Last year
Cell/Gene Tx

In the Lab: Re­gen­eron brings its an­ti­body chops to gene edit­ing's biggest prob­lem, aim­ing to 'change the field'

Last year
R&D

Can No­vo Nordisk's block­buster weight loss drug and oth­er GLP-1s al­so work in NASH? The an­swer is com­pli­cat­ed

Last year
R&D
Pharma

PacBio, once slat­ed to be ac­quired by Il­lu­mi­na, is tak­ing on the DNA gi­ant

Last year
Diagnostics
First page Previous page 123456 Next page Last page
A service from the Financial Times